Vikas Goyal

Vikas Goyal, Managing Partner and Co-Founder at Trekk Venture Partners

Vikas Goyal is a Managing Partner and Co-Founder at Trekk Venture Partners, a venture capital firm dedicated to investing in early stage biotech companies developing life-changing medicines.13 He has over 20 years of experience in the biotech industry, with a focus on corporate strategy, capital formation, corporate partnerships, and M&A for early stage therapeutics companies.1

Professional Experience

• Prior to co-founding Trekk, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, then joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company's acquisition by Merck for $1.85 billion in 2021.1

• Prior to Pandion, Vikas worked as an investor at SR One, GlaxoSmithKline's corporate venture unit, where he invested in and served on the boards of 19 early stage biotech companies including Morphic Therapeutics, River Vision Development (acquired by Horizon), Nimbus Therapeutics, Turning Point (acquired by BMS), Spero Therapeutics, and Pandion (acquired by Merck).12

• Previously, Vikas was a Consultant at McKinsey & Co's Pharmaceutical practice in New Jersey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals.1

Education

• Vikas earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in Neurobiology from Harvard University.1

• He is a member of the Kauffman Fellows Society (Class 17).12

Other Roles

• Vikas currently has an independent board role as a non-executive director of Slate Bio.1

• He is a member of the Kauffman Fellows Society (Class 17).12